According to a report that has not yet been peer reviewed, the COVID-19 vaccine developed by the pharmaceutical companies Pfizer and BioNTech is apparently effective against 16 separate coronavirus mutations.
The study by researchers at Pfizer and the University of Texas Medical Branch, as reported by Reuters, indicates that the vaccine may not need to be modified to function against what appears to be a more infectious coronavirus type that has arisen in the UK.
In the U.K. In individuals who had not traveled to the United Kingdom, the form, identified as B117, was recently detected in the United States, signaling population dissemination.
A common occurrence is viral mutations, and there is no proof that any mutations have made COVID-19 more hazardous than it is now. And while it is possible to adapt vaccines to fight new variants, there is no proof yet that this is important.
So we’ve tested 16 different mutations now, and none of them really had a major effect. That’s the good news,”So we’ve now tested 16 different mutations, and none of them really had a significant impact. That’s the good news,”That’s the good news. “But that doesn’t mean the 17th one won’t.”